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Abstract 
Purpose: To prepare transdermal ketoprofen metered-dose aerosol formulations containing menthol 
and isopropyl myristate (IPM) as penetration enhancers and to evaluate their physicochemical and 
permeation properties. 
Methods: Selected ratios of ketoprofen, ethanol, polyvinylpyrrolidone K30 (PVP K30, anti-nucleant), 
and penetration enhancers were mixed and filled into aluminum aerosol cans with hydrofluoroalkane-
134a as propellant. The physicochemical properties of the films, and their ex vivo permeation properties 
in rat skin were investigated over a 24-h period. Rat skin was exposed to a definite dose of each 
ketoprofen film to determine the quantity of drug in the receptor compartment over a 24-h period.  
Results: All the transdermal formulations showed good integrity and film uniformity. Formulations with 
permeation enhancers presented higher rates of skin penetration compared to control formulations. 
Formulations containing 3% PVP and 5% IPM produced the highest permeation rates (Jss, 85.35 
µg/cm2/h).  
Conclusion: These results indicate that incorporation of antinucleant polymer and permeation 
enhancers in aerosols containing ketoprofen enhances aerosol stability and drug permeation through rat 
skin.  
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The therapeutic level of drugs after transdermal 
exposure has been extensively studied [1-3].  
The stratum corneum is a major barrier to drug 
penetration through the skin. Since the lipid 
domain of stratum corneum is affected by 
chemical permeation enhancers, different 
chemical and biological enhancers that affect the 
lipid domain have been investigated [4-7]. 
Ketoprofen is a Non-Steroidal Anti-Inflammatory 
Drug (NSAID) which relieves inflammation-
induced pain, as well as vascular headache and 
dysmenorrhea. It is usually administered through 
the oral or rectal route [8]. Gastrointestinal 
complications such as ulcerations, abdominal 
burning sensation and pain, are some common 
side effects of ketoprofen [9]. To avoid these side 
effects, transdermal formulations, such as 
ketoprofen cream and ketoprofen ointment, have 
been developed for periodontal disease and 
osteopenia [10,11]. Percutaneous absorption of 
ketoprofen cream formulation and its effect on 
osteopenia have been studied [10-12]. 
Furthermore, the efficacies of different ointment 
bases and a new derivative of soy lecithin have 
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been investigated in the transdermal deliveries of 
drugs [13,14]. Indeed, investigations have been 
carried out on the effects of various topical 
formulations on different diseases, such as 
migraine, postoperative sore throat, and muscle 
soreness [15,16]. In recent years, transdermal 
metered-dose aerosols have been introduced as 
a new system of drug delivery to the skin. The 
advantage of transdermal aerosols over other 
topical routes of administration is the absence of 
any local irritation [17,18]. 
 
The purpose of this study was to prepare some 
transdermal aerosol formulations of ketoprofen 
and investigate their skin penetration capacities 






Ketoprofen was received as a gift from Iran 
Hormone Co., Tehran, Iran. Pure ethanol (99.7-
100%) and PVP K30 were purchased from 
Bidestan (Tehran, Iran) and Fulka, (Switzerland), 
respectively. In addition, 1,1,1,2-tetrafluorethane 
(HFA 134a) was kindly gifted from INEOS Flour, 
UK. Methanol and IPM were provided by Pars 
Daru (Tehran, Iran) and Sepidaj (Tehran, Iran), 
respectively. 
 
Formulation and preparation of metered-dose 
aerosol  
 
Metered-dose aerosol solutions were formulated 
by dispersing ketoprofen (as a filmforming 
polymer, PVP) and an enhancer in pure ethanol 
(Table 1). The compounds were mixed with a 
magnetic stirrer overnight to solvate the polymer. 
Thereafter, aliquots of the solutions were 
dispensed into aerosol containers (Bespak 
Europe Ltd., UK). A 63-µL valve was crimped on 
each container and the can was then filled with 
filtered HFA 134a. Ketoprofen concentrations 
were adjusted to 1.6-1.9 mg per puff, and pure 
ethanol was set at 1.0% (w/w). The latter allowed 
for reduction of negative effects on the vapor 
pressure and the release velocity of the liquefied 
propellant through the orifice. Each polymer film 
formation was tested by spraying it onto a clear 
plastic plate and allowing the solvent to 
evaporate. 
 
Optical microscopy  
 
The homogeneities of the solutions were 
observed using an optical microscope (Euromex, 
Netherlands) equipped with a camera system 
(Sony, Japan). The morphologies of the 
produced films were assessed before and after 
the films were filled into the cans. For this 
purpose, the formulation was sprayed and 
photographed. 
 
Table 1: Composition of transdermal metered-
dose aerosol formulations 
 





F1 5 5 - 
F2 7.5 7 - 
F3 5 - 5 
F4 7.5 - 5 
F5 7.5 - 5 
F6 5 - - 
F7 7.5 - - 
F8 3 5  
F9 3 7  
F10 3 - 2.5 
F11 3 - 5 
F12 3 - - 
The contents of ethanol (40%) and ketoprofen 
(5%) were the same in all the formulations. Each 
of the formulations was made up to 100% with 
HFA 134a  
 
Preparation of skin membranes  
 
The in vitro study was performed by using full-
thickness skins of 8-week-old male rats. The 
experimental protocols were approved by 
Institutional Review Board of Faculty of 
Pharmacy, Tehran University of Medical 
Sciences (ref no. 5074). The animals were 
handled according to EU Directive 2010/63/EU 
on the handling of animals used for scientific 
purposes [19]. Using a surgical blade, the skins 
were isolated by separating the underlying 
subcutaneous fat and connective tissue. The 
skins were kept frozen in a freezer at -20 °C until 
used. Prior to use, they were they were 
transferred to a room temperature setting. 
 
Drug permeation studies  
 
The skins were clamped in vertical Franz 
diffusion cells with a donor surface area of 3.8 
cm2 per skin, and maintained in a water bath at 
37 °C [20]. Phosphate-buffered saline (PBS, 23 
mL, pH 7.4) was used to fill the receptor 
compartment. Temperature was set at 37 °C 
throughout the 24-h experiment using a water 
bath. At the beginning of the diffusion 
experiments, 5 puffs of the ketoprofen 
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formulation were applied to the exposed area of 
the skin. Each sample (1 ml) was collected from 
the receptor compartment at 10 min, and at 1, 2, 
4, 6, 8 and 24 h post-dosing, and replaced with 1 
ml of fresh PBS. 
 
High-performance liquid chromatography 
(HPLC)  
 
HPLC was employed for the determination of 
drug concentration in each sample. Separation 
was carried out with 4:17 (v/v) ratio of phosphoric 
acid:methanol as a mobile phase at a flow rate of 
1.2 mL/min in an EC 250/4.6 Nucleodur 100-S 
C18ec column. The column temperature was set 
at 40 °C and injection volume was 100 μL. The 
peak area of chromatogram obtained at 256 nm 
was taken as reference for determination of drug 




The cumulative amounts of the drug that 
penetrated per unit surface area (µg/cm2) were 
analyzed as a function of time (h). The following 
formula was applied to calculate the in vitro skin 
permeation rate or steady state flux (Jss). 
 
Jss=ΔM/AΔt ……………………… (1) 
 
where ΔM is the amount of ketoprofen that 
penetrated through the skin within a defined time 
Δt, and A is the diffusional area. 
 
The cumulative amount of the absorbed drug in 
24 h was also measured. The effect of each 
penetration enhancer was represented by an 
Enhancement Ratio (ER), which was calculated 
as shown in Equation 2 below. 
 
ER = JssF/JssC ……………………….. (2) 
 
where JssF is the skin permeation of formulation 
with enhancer, and JssC is the skin permeation of 




The data are presented as mean ± standard 
deviation (SD). Differences between results 
obtained for formulations containing various 
excipients were statistically analyzed using 
Student´s t-test with the aid of SPSS 16.0 
statistical software. Differences were considered 




Characteristics of the formulations 
 
Tough films with smooth surfaces were produced 
by all the formulations. However, when examined 
under the microscope, all the films had some fine 
air bubbles. 
 
The cumulative amounts of ketoprofen that 
permeated from the films through the rat skin 
over 24 h were calculated by HPLC. The 
cumulative amounts of the drug release for all 
formulations with enhancers were significantly (p 
< 0.05) higher than for those without the 





Figure 1: Permeation profile (mean ± SD) of formulations prepared with 5 and 7.5% PVP (n = 3) 
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      Figure 2: Permeation profile (mean ± SD) of formulations prepared with 3% PVP (n = 3) 
 
Table 2: Permeation rate (Jss) and enhancement ratio 
(ER) of formulations prepared with 5 and 7.5% PVP 
 
Formulation Jss (µg/cm2/h) ER 
F1 3.64±0.017 1.10±0.026 
F2 8.71±0.144 3.24±0.033 
F3 12.39±0.104 3.75±0.046 
F4 3.87±0.139 1.44±0.035 
F5 3.66±0.009 1.37±0.018 
F6 3.30±0.070 - 
F7 2.68±0.030 - 
F8 85.36±0.663  79.38±0.683 
F9 10.71±0.549 9.96±0.566 
F10 61.14±0.786 56.86±0.81 
F11 6.97±0.358 6.48±0.369 
F12 1.08±0.017 - 
 
In the formulations with 5% PVP, F3 showed a 
significantly (p < 0.05) higher permeation rate 
than F1 (Table 2). Formulations with 7.5% PVP 
increased the permeation rate approximately as 
much as those of the formulations containing 5% 
PVP. 
 
Drug release, in the presence of lower amounts 
of PVP, were evaluated for formulations F8 to 
F12, with PVP concentration at 3%. As can be 
seen in Table 2, formulations with 3% PVP 
produced   significantly (p < 0.05) higher 
permeation than those with 5.0 - 7.5% PVP. 
 
Among all the formulations, F8 which contained 
5% IPM and 3% PVP had the highest permeation 
rate. This formulation showed a drastic rise in the 
amount of ketoprofen that permeated through the 




PVP is a well-known inhibitor of drug 
crystallization in pharmaceutical formulations. 
Many researchers have studied the inhibition 
mechanism of PVP in aqueous suspensions or 
solid dispersions [21, 22]. Amorphous drugs are 
in a high energy state that causes increased 
solubility and consequently a high 
thermodynamic activity and penetration rate [22]. 
At high concentrations of PVP, this effect may be 
reduced because of the interaction between the 
drug and PVP [23]. Thus, drug release in the 
presence of lower amounts of PVP was studied 
on formulations F8 to F12, where PVP 
concentration was lowered to 3%. This 
modification in the formulations resulted in a 
drastic rise in the amount of drug that permeated 
through the rat skin. Indeed, when the 
penetration enhancers were applied at the 
concentrations of 5% (for IPM) and 2.5% (for 
menthol), steady state flux reached values of 
85.35 and 61.13 µg/cm2/h, respectively. 
Therefore, in these series of studies, an optimal 
level of film former was identified so as to ensure 
the highest drug penetration rate for each 
enhancer. 
 
The presence of IPM or menthol in the films 
increased the flux of the drug, unlike in films 
without the enhancers. Calculation of ER for 
comparing the permeation rates of the drug in 
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the presence of the penetration enhancers 
revealed a considerable increase in the flux of 
the drug through the rat skin. The increased drug 
flux implies that the studied formulation would 
provide durable therapeutic effects.  This 
enhancement in drug activity can be due to a 
number of factors, such as the kinetics of the 
enhancer release from the film, and the 
interaction between the enhancers and other 
components of the film. These factors may 
induce varied effects depending on the amounts 
of polymers and enhancers [23]. Moreover, the 
enhancing effect depends on the composition of 
the formulation and the physicochemical features 
of drugs [24].  
 
Terpenes have been reported to increase the 
permeations of various groups of drugs, and 
amongst the terpenes, menthol enhances the 
penetrations of hydrophilic drugs [25,26]. The 
mechanisms involved in enhancement of drug 
penetration by terpenes include perturbations in 
the skin layer and lipid domains [27]. Various 
analogues of fatty acids have been studied as 
penetration enhancers [28]. Fatty acid esters 
generally affect drug permeation by increasing 
the fluidity of intracellular lipids [29]. In the 
present study, the penetration enhancers used, 
which are compatible with ethanol and HFA 
134a, were found to increase the penetration rate 
of ketoprofen after 8 h. This suggests that within 
8 h, the enhancers produced optimum effects by 
positioning themselves between the phospholipid 




The improved duration of release of high 
concentration of ketoprofen seen in this study is 
made possible by the formation of satisfactory 
films with the aid of PVP as an anti-nucleant. The 
films containing 5% IPM and 3% PVP is capable 
of enhancing skin permeation of ketoprofen up to 
79.38-fold in rats when compared with 
formulations without an enhancer. Thus, the 
formulations have a potential for transdermal 
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